恩替卡韦治疗失代偿期乙型肝炎肝硬化

Entecavir therapy in patients with decompensated HBV-related cirrhosis

目的探讨恩替卡韦治疗失代偿期乙型肝炎(乙肝)肝硬化临床疗效。方法选取失代偿期乙肝肝硬化患者共44例,随机分为治疗组22例,对照组22例。2组均给予还原型谷胱甘肽、促肝细胞生长素、甘草酸二铵等综合性保肝、护肝治疗。对照组加拉米夫定100mg,口服,1/d;治疗组加恩替卡韦0.5mg,口服,1/d。疗程均为52周。结果2组患者在HBVDNA水平下降,改善肝功能、血清肝纤维化指标、凝血酶原活动度及Child-Pugh积分等方面与治疗前比较,有统计学意义;2组治疗后比较,无统计学意义。结论恩替卡韦治疗失代偿期乙肝肝硬化患者,疗效明确,安全性好。

Objective To evaluate the effect of entecavir on patients with decompensated hepatitis B virus （HBV）-related cirrhosis. Methods A total of 44 cases of decompensated HBV-related cirrhosis were randomly divided into a treatment group （n=22） and a con- trol group （n=22）. Based on a comprehensive liver-preventing treatment regimen, including reduced glutathione, hepatoeyte growth factor and diammonium glycyrrhizinate in both groups, the patients in the treatment group were treated with entecavir （0.5 mg, l/d）, while those in the control group were given lamivudine （100 rag, i/d） for 52 weeks. Results Viral load, liver function, serum fibrosis indexes, thrombinogen activity and Child-Pugh score improved significantly compared with those before antiviral treatment （P〈 0.05）. No significant differences were found between the two groups after antiviral treatment （P〉0.05）. Conclusion Entecavir is effective and safe for patients with decompensated HBV-related cirrhosis.